The HF-AF ENERGY Trial: Attenuate atrial fibrillation with nicotinamide riboside (niagen)

Recruiting

• Conditions: Atrial fibrillation; 10007521

• Registration Number: NL-OMON52394
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

• Patients diagnosed with paroxysmal or persistent AF
• Left ventricle function <=40%
• Implantable cardiac device (ICD) equipped with rhythm monitoring software
• Ischemic and/or non-ischemic cardiomyopathy
• Aged between 18-90 years

Exclusion Criteria

• Permanent AF
• Hemodynamic instability
• Absence of atrial sensing
• Malabsorption diseases
• Metabolic diseases
• Inflammatory disease

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Our primary objective is to investigate whether niagen normalizes blood-based<br /><br>energy metabolites, mitochondrial levels, and proteostasis levels. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>To examine whether niagen reduces AF burden in patients with ischemic and/or<br /><br>non-ischemic heart disease. </p><br>